Literature DB >> 1697499

Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects.

S Wadler1, R Wersto, V Weinberg, D Thompson, E L Schwartz.   

Abstract

Fluorouracil (FUra) is the most active agent in advanced colorectal carcinoma, and this activity can be enhanced by various modulating agents both in vitro and in vivo. To determine whether interferon (IFN) is capable of augmenting the cytotoxic and cytokinetic effects of FUra, combinations of FUra and IFN alpha, -beta, and -gamma were tested against 2 human colon cancer cell lines in vitro. In a clonogenic assay, IFN alpha and -beta, at concentrations that produced less than 1 log cell kill, significantly increased the cytotoxic effects of FUra in both cell lines. IFN gamma also enhanced the cytotoxic effects of FUra, but unlike IFN alpha and -beta, only at the highest concentrations tested. Median effects analysis demonstrated that all 3 IFNs exhibited synergy with FUra. Combinations of IFNs were no more effective at modulating FUra activity than single agent IFN. Flow cytometric studies indicated that these effects did not correlate with cytokinetic alterations. Only the combination of FUra and IFN beta produced cytokinetic effects different from those of FUra alone. Incubation with IFN alpha or IFN gamma for 24 h resulted in only modest cytokinetic alterations, and they did not modify the effects of FUra. These results indicate that IFN is capable of increasing the cytotoxic actions of FUra and that this is separable from any cytokinetic effects produced by the interferons.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1697499

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

Review 1.  Immunotherapy in metastatic renal cell carcinoma.

Authors:  Karl Rohrmann; Michael Staehler; Nikolas Haseke; Alexander Bachmann; Christian G Stief; Michael Siebels
Journal:  World J Urol       Date:  2005-04-02       Impact factor: 4.226

2.  Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases.

Authors:  H Tada; D J Maron; E A Choi; J Barsoum; H Lei; Q Xie; W Liu; L Ellis; A D Moscioni; J Tazelaar; S Fawell; X Qin; K J Propert; A Davis; D L Fraker; J M Wilson; F R Spitz
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

3.  Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.

Authors:  Z Gazit; D W Weiss; D Shouval; M Yechezkeli; V Schirrmacher; M Notter; J Walter; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 4.  Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches.

Authors:  A J Schrader; Z Varga; A Hegele; S Pfoertner; P Olbert; R Hofmann
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-25       Impact factor: 4.553

5.  Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031.

Authors:  V J Picozzi; R A Abrams; P A Decker; W Traverso; E M O'Reilly; E Greeno; R C Martin; L S Wilfong; M L Rothenberg; M C Posner; P W T Pisters
Journal:  Ann Oncol       Date:  2010-07-29       Impact factor: 32.976

6.  Effects of 5-fluorouracil, leucovorin, and glucarate in rat colon-tumor explants.

Authors:  T D Schmittgen; A Koolemans-Beynen; T E Webb; T J Rosol; J L Au
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-alpha-2a in patients with advanced malignancies.

Authors:  S Wadler; H Haynes; R Schechner; A Rozenblit; P H Wiernik
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

8.  Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.

Authors:  E E Vokes; S M O'Brien; N J Vogelzang; R L Schilsky; M J Ratain
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Krüppel-like factor 9 (KLF9) prevents colorectal cancer through inhibition of interferon-related signaling.

Authors:  Adam R Brown; Rosalia C M Simmen; Vinay R Raj; Trang T Van; Stewart L MacLeod; Frank A Simmen
Journal:  Carcinogenesis       Date:  2015-07-25       Impact factor: 4.944

10.  Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study.

Authors:  C J Punt; P H de Mulder; J T Burghouts; D J Wagener
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.